<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Medical management of low-risk adult patients with mild to moderate ulcerative colitis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Medical management of low-risk adult patients with mild to moderate ulcerative colitis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Medical management of low-risk adult patients with mild to moderate ulcerative colitis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jana Al Hashash, MD, MSc, FACG, AGAF
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Miguel Regueiro, MD, AGAF, FACG, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sunanda V Kane, MD, MSPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 22, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ulcerative colitis (UC) is a chronic inflammatory condition characterized by relapsing episodes of inflammation limited to the mucosal layer of the colon. The rectum is usually affected, and inflammation may extend in a proximal and continuous fashion to involve other portions of the colon.
        </p>
        <p>
         This topic will review the medical management of mild to moderate UC. Health maintenance for patients with inflammatory bowel disease (IBD) is also discussed. The management of high-risk patients with moderate to severe UC is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">
          "Management of moderate to severe ulcerative colitis in adults"
         </a>
         .)
        </p>
        <p>
         The management of patients with acute, severe UC is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">
          "Management of the hospitalized adult patient with severe ulcerative colitis"
         </a>
         .)
        </p>
        <p>
         The surgical management of UC is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1375.html" rel="external">
          "Surgical management of ulcerative colitis"
         </a>
         .)
        </p>
        <p>
         The clinical manifestation and diagnosis of UC are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"
         </a>
         .)
        </p>
        <p>
         Adjustments to medication regimens for patients with IBD and suspected or known coronavirus disease 19 (COVID-19) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/127965.html" rel="external">
          "COVID-19: Issues related to gastrointestinal disease in adults"
         </a>
         .)
        </p>
        <p>
         The American Gastroenterological Association and the American College of Gastroenterology have published guidelines on management of UC [
         <a href="#rid1">
          1-3
         </a>
         ]. Our approach is generally consistent with society guidelines; however, if differences exist, they are noted.
        </p>
        <p class="headingAnchor" id="H1226801754">
         <span class="h1">
          DISEASE ACTIVITY, SEVERITY, AND RISK
         </span>
        </p>
        <p class="headingAnchor" id="H2128341423">
         <span class="h2">
          Defining disease activity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical trials of UC often use formal grading systems to describe disease activity. The severity of UC is generally classified as mild, moderate, or severe disease; however, the definition of mild to moderate disease activity may vary in the literature depending on the specific index or score being used (eg, Truelove and Witts severity index [
         <a href="#rid4">
          4
         </a>
         ], Mayo Clinic score [
         <a href="#rid5">
          5
         </a>
         ], Montreal classification [
         <a href="#rid6">
          6
         </a>
         ]).
        </p>
        <p>
         In clinical practice, the following definitions may be more useful:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild
         </strong>
         – Patients with mild clinical disease have ≤4 stools per day with or without small amounts of blood, no signs of systemic toxicity (eg, no tachycardia), and a normal C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR). Mild crampy abdominal pain, tenesmus, and periods of constipation are also common, but severe abdominal pain, profuse bleeding, fever, and weight loss are not part of the spectrum of mild disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate
         </strong>
         – Patients with moderate clinical disease may have frequent (four to six per day), loose, bloody stools, mild anemia not requiring blood transfusions (hemoglobin &gt;10 g/dL), and abdominal pain that is not severe. Patients have no or minimal signs of systemic toxicity. Adequate nutrition is usually maintained and weight loss is not associated with moderate clinical disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe
         </strong>
         – Patients with a severe clinical disease typically have frequent, loose bloody stools (≥6 per day) with severe cramps and evidence of systemic toxicity as demonstrated by a fever (temperature ≥37.8°C), tachycardia (heart rate ≥90 beats per minute), anemia (hemoglobin &lt;10 g/dL), and/or an elevated CRP or ESR. Patients may have weight loss. The management of acute, severe UC is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">
          "Management of the hospitalized adult patient with severe ulcerative colitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3899685799">
         <span class="h2">
          Defining disease extent
         </span>
         <span class="headingEndMark">
          —
         </span>
         Terminology to describe the extent of involvement of UC includes [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4072.html" rel="external">
          "Endoscopic diagnosis of inflammatory bowel disease in adults", section on 'Differentiating ulcerative colitis from Crohn disease'
         </a>
         .):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ulcerative proctitis
         </strong>
         – Ulcerative proctitis refers to disease within 18 cm of the anal verge, distal to the rectosigmoid junction
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ulcerative proctosigmoiditis
         </strong>
         – Ulcerative proctosigmoiditis refers to disease limited to the rectum and sigmoid colon and not involving the descending colon
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Left-sided colitis
         </strong>
         – Left-sided colitis refers to disease that extends beyond the sigmoid colon and as far proximally as the splenic flexure
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extensive colitis
         </strong>
         – Extensive colitis refers to disease extending proximal to the splenic flexure
        </p>
        <p>
        </p>
        <p>
         Colonoscopy is required to determine the extent of involvement, and the distribution of mucosal inflammation may progress over time [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1348370983">
         <span class="h2">
          Low- versus high-risk patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the clinical parameters, the American Gastroenterological Association stratifies patients into either a low or high risk category by assessing inflammatory status with the following tests [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endoscopic evaluation for mucosal ulcerations and disease extent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory studies (eg, fecal calprotectin)
        </p>
        <p>
        </p>
        <p>
         For patients with mild to moderate UC, the following features may predict a lower risk for long-term sequelae (eg, colectomy) [
         <a href="#rid1">
          1,9,10
         </a>
         ]. (See
         <a class="local">
          'Defining disease extent'
         </a>
         above.):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild or moderate symptoms (≤6 stools daily with or without blood)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No systemic symptoms (eg, fever, weight loss)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lack of severe endoscopic disease (eg, lack of deep ulcerations)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal or mild elevation in CRP, ESR, and/or fecal calprotectin levels
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No extraintestinal manifestations
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diagnosis at age &gt;40 years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal albumin
        </p>
        <p>
        </p>
        <p>
         Patients initially identified as low risk may be subsequently reclassified as high risk if they develop complications or do not respond to initial treatment. Other prognostic factors associated with a more complicated disease course include number of flares, need for glucocorticoids, number of hospitalizations related to UC, and infection with
         <em>
          Clostridioides
         </em>
         <em>
          difficile
         </em>
         or cytomegalovirus [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p>
         Management of high-risk, ambulatory patients with moderate to severe UC or patients with acute severe UC is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">
          "Management of moderate to severe ulcerative colitis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">
          "Management of the hospitalized adult patient with severe ulcerative colitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2610235645">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapy for UC is guided by pretreatment evaluation (laboratory studies and lower endoscopy), and the goals are to exclude alternative or coexisting conditions and determine the extent and severity of disease.
        </p>
        <p>
         When a patient with UC presents with symptoms of a disease flare (eg, diarrhea, rectal bleeding), some aspects of the initial evaluation (eg, laboratory and stool studies, lower endoscopy) should be repeated to exclude other conditions as a cause for symptoms and to assess the extent and severity of disease. We begin by assessing the patient's risk factors for other etiologies of colitis, such as use of nonsteroidal anti-inflammatory drugs or antibiotics, recent travel to endemic areas, or ingestion of raw meat or fish.
        </p>
        <p>
         Our approach to diagnostic testing includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory testing
         </strong>
         – We typically obtain complete blood count, liver biochemical tests, albumin, and C-reactive protein (CRP). While CRP as a serologic marker of inflammation has largely replaced ESR, both may be sent in combination, and in rare circumstances, clinicians may only have access to ESR [
         <a href="#rid11">
          11-13
         </a>
         ]. For example, a normal CRP in a patient with recurrent symptoms (who previously had elevated CRP in the setting of active mucosal inflammation) suggests a noninflammatory etiology (eg, functional symptoms) [
         <a href="#rid13">
          13-15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15930.html" rel="external">
          "Approach to functional gastrointestinal symptoms in adults with inflammatory bowel disease", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stool studies
         </strong>
         – We typically obtain stool testing for inflammation (ie, fecal calprotectin) and for infection (ie,
         <em>
          Clostridioides
         </em>
         [formerly
         <em>
          Clostridium
         </em>
         ]
         <em>
          difficile
         </em>
         , routine stool cultures [
         <em>
          Salmonella
         </em>
         , S
         <em>
          higella
         </em>
         ,
         <em>
          Campylobacter
         </em>
         ,
         <em>
          Yersinia
         </em>
         ], and specific testing for
         <em>
          E. coli
         </em>
         O157:H7). For patients with risk factors for parasitic infection (eg, recent travel to a region where parasitic infections are endemic), stool microscopy for ova and parasites (three specimens) and a
         <em>
          Giardia
         </em>
         stool antigen test are also checked. Stool analysis for the detection of pathogens is discussed in more detail separately:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2699.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in adults: Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2717.html" rel="external">
          "Approach to the adult with acute diarrhea in resource-abundant settings"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5723.html" rel="external">
          "Giardiasis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14001.html" rel="external">
          "Approach to stool microscopy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to lower endoscopy
         </strong>
         – Lower endoscopy may be needed, and the approach to repeating the endoscopic evaluation depends on the time interval between the patient's previous lower endoscopy and the onset of symptoms, the severity of the patient's symptoms, and duration of symptoms. (See
         <a class="local">
          'Defining disease activity'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">
          "Management of moderate to severe ulcerative colitis in adults", section on 'Defining overall disease activity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients without severe symptoms
         </strong>
         –
         <strong>
         </strong>
         We typically perform colonoscopy for ambulatory patients without severe symptoms (eg, &lt;6 stools daily with or without blood, no systemic symptoms) who have had their previous colonoscopy (or flexible sigmoidoscopy) &gt;6 months prior to presentation. A flexible sigmoidoscopy is an acceptable alternative, particularly for patients who have a history of disease limited to distal colon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients without severe symptoms who have had a colonoscopy within the previous six months, we use inflammatory markers (CRP and fecal calprotectin) to reassess disease activity. Inflammatory markers with values within the reference range generally indicate that mucosal disease has remained in remission, and this usually obviates the need for repeating endoscopic evaluation. If an inflammatory marker is elevated, we generally initiate treatment for a flare of UC without repeating endoscopic evaluation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ambulatory patients with severe symptoms
         </strong>
         –
         <strong>
         </strong>
         We typically perform lower endoscopy without bowel preparation for patients with severe gastrointestinal symptoms (eg, frequent loose bloody stools [≥6 per day]) because they may require escalation of therapy. Lower endoscopy with mucosal biopsies is typically performed to assess the severity and extent of inflammation and to exclude an infection (eg, cytomegalovirus [CMV]). (See
         <a class="medical medical_review" href="/z/d/html/8305.html" rel="external">
          "Approach to the diagnosis of cytomegalovirus infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our practice is to use a pediatric colonoscope and carbon dioxide for insufflating the bowel. If mucosal disease is severe (eg, diffuse ulceration and friability) or looping of the colonoscope is encountered, the extent of the examination is limited to the sigmoid colon. Looping of the colonoscope occurs due to the attachment of the sigmoid and transverse colon to a mobile mesentery, and endoscopic techniques and associated risks are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13927.html" rel="external">
          "Overview of colonoscopy in adults", section on 'Colonoscope advancement and mucosal inspection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the endoscopic evaluation is proceeding without difficulty and if the distal mucosal disease is not severe (eg, absence of deep ulcerations), the pediatric colonoscope is advanced beyond the sigmoid colon. (See
         <a class="medical medical_review" href="/z/d/html/4072.html" rel="external">
          "Endoscopic diagnosis of inflammatory bowel disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acutely ill, hospitalized patients with severe symptoms
         </strong>
         – For hospitalized patients with acute severe colitis, we usually perform a flexible sigmoidoscopy without a bowel preparation to assess the severity of mucosal disease, and we obtain biopsies to exclude infection (eg, CMV). Colonoscopy is generally not required because of the potentially increased risk of perforation especially if the mucosa is severely inflamed [
         <a href="#rid16">
          16
         </a>
         ]. The management of acutely ill patients with UC is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">
          "Management of the hospitalized adult patient with severe ulcerative colitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H432583317">
         <span class="h1">
          INDUCTION OF REMISSION
         </span>
        </p>
        <p class="headingAnchor" id="H1291403062">
         <span class="h2">
          Goals of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment goal for patients with active UC is to achieve remission (endoscopic and clinical remission) by demonstrating complete mucosal healing. Although the treatment goals for UC are symptomatic improvement (ie, resolution of diarrhea and bleeding) and endoscopic healing, histologic improvement is emerging as an important component of disease remission [
         <a href="#rid2">
          2
         </a>
         ]. Response to therapy can be determined by assessing symptoms, laboratory testing, and supplemented by endoscopy with biopsies as needed. (See
         <a class="local">
          'Monitoring during remission'
         </a>
         below.)
        </p>
        <p>
         Initial treatment of UC is based upon disease severity and extent. (See
         <a class="local">
          'Disease activity, severity, and risk'
         </a>
         above.) Most patients with mild to moderate UC respond to 5-aminosalicylic acid (5-ASA) with or without an induction course of oral or topical glucocorticoids. (See
         <a class="local">
          'Ulcerative proctitis or proctosigmoiditis'
         </a>
         below and
         <a class="local">
          'Left-sided or extensive colitis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H113301576">
         <span class="h2">
          Ulcerative proctitis or proctosigmoiditis
         </span>
        </p>
        <p class="headingAnchor" id="H100504367">
         <span class="h3">
          Initial therapy
         </span>
        </p>
        <p class="headingAnchor" id="H3785594826">
         <span class="h4">
          Topical mesalamine
         </span>
         <span class="headingEndMark">
          —
         </span>
         We and several society guidelines prefer topical (rectal)
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         as first-line treatment for inducing remission in low-risk patients with mild to moderate ulcerative proctitis or proctosigmoiditis  (
         <a class="graphic graphic_table graphicRef86774" data-inline-graphics="86774" href="/z/d/graphic/86774.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          Mesalamine
         </a>
         is widely available in two forms: suppository or enema. Foam and gel preparations of mesalazine (ie, the international generic name) are available in countries outside the United States [
         <a href="#rid17">
          17,18
         </a>
         ]. Enemas reach the proximal sigmoid colon and splenic flexure in most patients who are able to retain them [
         <a href="#rid19">
          19
         </a>
         ]. By contrast, foam preparations generally reach the midsigmoid colon [
         <a href="#rid20">
          20
         </a>
         ], while suppositories are effective only for disease limited to the rectum (ie, within 18 cm from the anal verge).
        </p>
        <p>
         Outpatient therapy is appropriate for most patients, and choice of a specific treatment will depend upon the distribution of disease  (
         <a class="graphic graphic_table graphicRef86774" href="/z/d/graphic/86774.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ulcerative proctitis
         </strong>
         – For patients with mild to moderate disease confined to the rectum, we begin with
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         suppository, 1 gram once daily  (
         <a class="graphic graphic_algorithm graphicRef138644" data-inline-graphics="138644" href="/z/d/graphic/138644.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid21">
          21,22
         </a>
         ]. For patients who do not have symptomatic relief after an initial two-week course of mesalamine suppositories, we increase the dose to 1 gram twice daily for two to four weeks. We then reduce the dose of the mesalamine suppository to 1 gram daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ulcerative proctosigmoiditis
         </strong>
         – For patients with mild to moderate disease extending above 18 cm from anal verge into the sigmoid colon, we begin with
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         enemas administered rectally once daily. For patients with fecal urgency and tenesmus, we also begin mesalamine suppository 1 gram once daily. Patients who cannot retain enemas due to rectal irritability may use a mesalamine foam preparation (available in Canada). Rectal glucocorticoid foam preparations are also an option for a short course (two to four weeks) of induction therapy for patients who cannot retain mesalamine enemas. (See
         <a class="local">
          'Alternative therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients without symptomatic relief after two weeks of daily
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         enemas, we either increase the mesalamine enema to twice daily or continue once daily enema and add a mesalamine suppository 1 gram once daily, depending on patient preference. Twice daily topical mesalamine dosing is given for four weeks, followed by resuming the once daily mesalamine enema.
        </p>
        <p>
        </p>
        <p>
         Symptomatic improvement (eg, decrease in bleeding and stool frequency) can be expected within one week of initiating topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         therapy. However, clinical remission usually requires four to six weeks or longer, and we continue topical mesalamine treatment to maintain remission. (See
         <a class="local">
          'Maintenance of remission'
         </a>
         below.)
        </p>
        <p>
         Topical (rectal)
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         is effective for inducing remission in patients with mild to moderate proctitis or proctosigmoiditis [
         <a href="#rid23">
          23,24
         </a>
         ]. In a meta-analysis of eight trials including 811 patients, patients treated with rectal mesalamine were more likely to achieve symptomatic remission compared with patients given placebo (pooled odds ratio [OR] 8.3, 95% CI 4.28-16.12) [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         In addition, topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         preparations are preferred over oral 5-ASA therapy and over topical (rectal) glucocorticoids [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis of three trials including 155 patients with distal UC or proctitis, patients treated with topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         were less likely to lack clinical improvement compared with patients treated with oral agents (mesalamine 2 to 3 grams daily or
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         4 grams daily) (relative risk [RR] 0.28, 95% CI 0.14-0.56) [
         <a href="#rid23">
          23,25-27
         </a>
         ]. Sulfasalazine is a prodrug composed of 5-ASA linked to sulfapyridine through an azo bond  (
         <a class="graphic graphic_figure graphicRef76617" href="/z/d/graphic/76617.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">
          "Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease", section on 'Pharmacology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis of six trials, patients with distal UC treated with topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         were more likely to achieve symptomatic remission compared with those on topical glucocorticoids (OR 1.65, 95% CI 1.11-2.45) [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H777082426">
         <span class="h4">
          Alternative therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alternative agents are available as initial therapy for patients with a hypersensitivity to topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         or for patients who are unable or unwilling to use topical therapies in general:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical glucocorticoids
         </strong>
         – Patients who cannot tolerate topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         but who can use rectal therapy are treated with topical glucocorticoids, and the formulation depends on disease extent  (
         <a class="graphic graphic_table graphicRef86774" href="/z/d/graphic/86774.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ulcerative proctitis
         </strong>
         – If disease is limited to the rectum (≤18 cm from the anal verge), we use a glucocorticoid suppository (ie,
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         ) once daily for two weeks for induction of remission. For patients without symptomatic relief after two weeks, we increase the dosing frequency to twice daily for ≤4 weeks, followed by decreasing the frequency to once daily for ≤2 weeks, and then discontinue it. We limit the duration of use to ≤8 weeks because of the potential for systemic side effects (eg, adrenal suppression) with topical glucocorticoids.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ulcerative proctosigmoiditis
         </strong>
         – If colitis extends beyond 18 cm from the anal verge, we typically use a glucocorticoid foam preparation or glucocorticoid enema once daily [
         <a href="#rid1">
          1,28
         </a>
         ]. For patients without symptomatic relief after two weeks of therapy, glucocorticoid enemas are given twice daily for ≤4 weeks and then decreased to daily use for ≤2 weeks. We limit the duration of topical glucocorticoid use to ≤8 weeks because of the potential for systemic side effects. Alternatively, a twice daily regimen consisting of glucocorticoid suppository in the morning and a glucocorticoid enema (or foam) preparation at bedtime is an alternative to twice daily enemas for patient convenience. The specific regimen of topical glucocorticoids is often based on patient preferences, product availability, insurance coverage/cost, and clinician preference. (See
         <a class="medical medical_review" href="/z/d/html/4061.html" rel="external">
          "Overview of budesonide therapy for adults with inflammatory bowel disease", section on 'Rectal formulations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Symptomatic improvement (eg, decreased bleeding and stool frequency) is usually seen three to four weeks after starting topical glucocorticoid therapy. Long-term use (ie, &gt;8 weeks) is generally avoided because the efficacy has not been established and may be associated with adverse effects of chronic topical glucocorticoid use [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral 5-ASA agents
         </strong>
         – Patients who are unwilling or unable to tolerate topical medications can be treated with an oral 5-ASA medication  (
         <a class="graphic graphic_table graphicRef86774" href="/z/d/graphic/86774.html" rel="external">
          table 1
         </a>
         ). We prefer to begin with high-dose
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         (ie, &gt;3 grams daily), while
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         (4 grams daily) is an alternative option especially in patients with inflammatory bowel disease-associated arthritis [
         <a href="#rid30">
          30,31
         </a>
         ]. We prefer using oral mesalamine once daily dosing to optimize patient adherence (similar to society guidelines) [
         <a href="#rid1">
          1
         </a>
         ]. The selection of a specific formulation of mesalamine also depends on insurance coverage/cost, product availability, convenience of dosing, and clinician preference. After remission is achieved (typically within eight weeks), decreasing the mesalamine dose to 2 to 3 grams per day is reasonable, whereas continuing the high dose is acceptable also.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While we use high-dose
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         (ie, &gt;3 grams daily) for induction therapy, some society guidelines prefer either mesalamine at standard dose (ie, 2 to 3 grams daily) or diazo-bonded 5-ASA (eg,
         <a class="drug drug_general" data-topicid="8713" href="/z/d/drug information/8713.html" rel="external">
          balsalazide
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. The formulations, pharmacology and adverse effects of 5-ASA agents are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">
          "Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Oral
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         at either a standard (2 to 3 grams daily) or high (&gt;3 grams daily) dose is effective for inducing remission for patients with mild to moderate UC. In a meta-analysis, the risk of failing to achieve remission was lower in patients on either high or standard dose mesalamine compared with patients given placebo (high dose, six trials including 904 patients: RR of failure to achieve remission 0.75, 95% CI 0.66-0.86; standard dose, eight trials including 1199 patients: RR 0.84, 95% CI 0.78-0.91) [
         <a href="#rid23">
          23
         </a>
         ]. In addition, the risk of failing to achieve remission was lower in patients given high-dose or standard-dose mesalamine compared with low-dose mesalamine (&lt;2 grams daily) (high dose, six trials including 519 patients: RR 0.81, 95% CI 0.71-0.92; standard dose, eight trials including 906 patients: RR 0.88, 95% CI 0.79-0.99) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H590904340">
         <span class="h3">
          Subsequent therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who tolerate topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         but who do not have improvement in symptoms after four weeks of therapy, subsequent options include  (
         <a class="graphic graphic_table graphicRef86774" href="/z/d/graphic/86774.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid26">
          26,32
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Add a topical glucocorticoid (eg, suppository, enema) once daily to the existing topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         ,
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Add an oral 5-ASA agent to the existing topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         regimen, or
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Start an oral glucocorticoid (ie,
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         multimatrix [MMX] or
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         For example, topical therapy is given twice daily (ie, glucocorticoid once daily and
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         daily) for patients without symptomatic improvement after four weeks of topical mesalamine alone. If there is no symptomatic improvement after two to four weeks of the topical glucocorticoid/mesalamine regimen, we then add an oral 5-ASA agent while continuing topical therapy. The approach to initiating oral 5-ASA therapy and the efficacy of such therapy is described above. (See
         <a class="local">
          'Alternative therapy'
         </a>
         above.)
        </p>
        <p>
         If there is no improvement after two to four weeks, we start an oral glucocorticoid. Patients who fail to respond to combination therapy with oral 5-ASA agent and topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         (and/or topical glucocorticoids) require treatment with oral glucocorticoids, as discussed below. (See
         <a class="local">
          'Subsequent therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Left-sided or extensive colitis
         </span>
        </p>
        <p class="headingAnchor" id="H777082449">
         <span class="h3">
          Initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We use a combination of an oral 5-ASA agent plus rectal
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         for patients with left-sided or extensive mildly to moderately active UC. Symptomatic improvement is usually seen within two to four weeks.
        </p>
        <p>
         We prefer to begin high-dose
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         (ie, &gt;3 grams daily) as the initial oral therapy for patients with left-sided colitis or extensive colitis;
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         4 grams per day is an alternative option [
         <a href="#rid30">
          30,31
         </a>
         ]. Our practice differs from the American Gastroenterological Association guideline that recommends initial oral therapy with either standard dose mesalamine (ie, 2 to 3 grams daily) or diazo-bonded 5-ASA (eg,
         <a class="drug drug_general" data-topicid="8713" href="/z/d/drug information/8713.html" rel="external">
          balsalazide
         </a>
         ) [
         <a href="#rid1">
          1,33
         </a>
         ]. (See
         <a class="local">
          'Alternative therapy'
         </a>
         above.)
        </p>
        <p>
         Different formulations of oral 5-ASA agents have been developed for site-specific, targeted delivery of 5-ASA. The 5-ASA formulations include
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         (a prodrug of 5-ASA), and diazo-bonded 5-ASA  (
         <a class="graphic graphic_table graphicRef86774" href="/z/d/graphic/86774.html" rel="external">
          table 1
         </a>
         ). The formulations and adverse effects of 5-ASA agents, including details regarding folate supplementation with sulfasalazine use, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">
          "Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
         For topical therapy, we use
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         enemas once daily initially for two months. Deciding whether to continue mesalamine enemas after achieving remission is based on patient preference and tolerance. For patients who cannot retain enemas due to rectal irritability, 5-ASA foam preparations or 5-ASA rectal suppositories are alternatives.
        </p>
        <p>
         Patients who are given both 5-ASA oral and topical therapy are less likely to fail to achieve remission compared with patients on oral 5-ASA monotherapy [
         <a href="#rid26">
          26,34-36
         </a>
         ]. In a meta-analysis of four trials including 321 patients with left-sided or extensive colitis, combined oral and topical 5-ASA therapy was less likely to fail to induce remission compared with oral 5-ASA (or
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         ) alone (RR 0.68, 95% CI 0.49-0.94) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Subsequent therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following are treatment options for patients who do not respond (ie, minimal to no improvement in symptoms such as diarrhea, rectal bleeding) after two to four weeks of combination therapy consisting of oral 5-ASA agent and rectal
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         (
         <a class="graphic graphic_table graphicRef86774" href="/z/d/graphic/86774.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral 5-ASA agent plus topical (rectal) glucocorticoids
         </strong>
         – For patients who do not respond to combination therapy, topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         can be replaced with topical glucocorticoid therapy (enema, foam, or suppository daily), while the oral 5-ASA agents are continued.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          Budesonide
         </a>
         <strong>
          multimatrix
         </strong>
         – For patients who do not respond to a combination of oral 5-ASA and topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         (or topical glucocorticoids), budesonide MMX can be added to the existing regimen. We give budesonide MMX at a dose of 9 mg daily for eight weeks and then stop it without a taper [
         <a href="#rid37">
          37
         </a>
         ]. For patients who develop symptoms of relapse (eg, diarrhea, rectal bleeding) at ≥8 weeks after discontinuing budesonide, a second course of budesonide (9 mg daily for eight weeks) is given. If symptoms improve with treatment, we discontinue budesonide without a taper. An alternative approach used by some clinicians for the second budesonide course is to taper budesonide MMX as follows: 9 mg daily for four weeks; then 9 mg every other day for two weeks; and then 9 mg every third day for two weeks (ie, total of eight weeks for the second course of therapy). However, there are no data to support this gradual dose reduction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who cannot stop
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         due to symptom recurrence within eight weeks of discontinuation require escalation of therapy to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (discussed below) or a biologic agent, which is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">
          "Management of moderate to severe ulcerative colitis in adults", section on 'Induction of remission'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Colonic release
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         is effective for inducing remission for patients with UC, and budesonide MMX formulation extends its delivery to the entire colon. In a meta-analysis of three trials including 479 patients, budesonide MMX at 9 mg daily for eight weeks was more effective for inducing endoscopic and clinical remission in patients with mild to moderate UC compared with placebo (RR of failure to induce remission 0.88, 95% CI 0.83-0.94) [
         <a href="#rid23">
          23,37-39
         </a>
         ]. Long-term efficacy and safety data for maintaining remission with budesonide MMX are lacking, and thus it is only used as induction therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of glucocorticoids with a high first-pass metabolism and lower risk of adverse effects is preferred over systemic glucocorticoids, and the pharmacology, dosing, and safety of
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4061.html" rel="external">
          "Overview of budesonide therapy for adults with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         – For patients whose symptoms do not improve with
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         MMX, we discontinue budesonide MMX and initiate systemic glucocorticoid therapy with prednisone. Oral prednisone is started at a dose of 40 mg daily, and we typically begin to taper prednisone after one week of high-dose therapy. However, some clinicians continue high-dose glucocorticoid therapy for up to four weeks prior to initiating a taper. We generally taper prednisone by either 5 mg or 10 mg increments on a weekly basis for a total duration of four to eight weeks of therapy. For patients who have been treated with glucocorticoids for greater than three months, a slower taper may be needed to avoid adrenal insufficiency, and this is discussed separately [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7983.html" rel="external">
          "Glucocorticoid withdrawal"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         typically results in symptomatic improvement within one week. However, prednisone is not given as long-term therapy because of the risk of adverse effects [
         <a href="#rid41">
          41
         </a>
         ]. Patients are regarded as having steroid-dependent UC if glucocorticoids cannot be tapered to less than 10 mg daily within three months of starting glucocorticoids without recurrence of disease or if relapse occurs within three months of stopping glucocorticoids [
         <a href="#rid42">
          42
         </a>
         ]. Such patients typically require escalation to other therapies for long-term maintenance (eg, biologic agents), and this is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">
          "Management of moderate to severe ulcerative colitis in adults", section on 'Induction of remission'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Oral glucocorticoids are effective for inducing remission in patients with active UC. In a meta-analysis of three trials including 247 patients, the risk of failing to achieve remission was lower for patients treated with glucocorticoids compared with placebo (RR 0.47, 95% CI 0.24-0.90) [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3834857877">
         <span class="h1">
          MAINTENANCE OF REMISSION
         </span>
        </p>
        <p class="headingAnchor" id="H2195340501">
         <span class="h2">
          Goals of and indications for therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         After clinical remission has been achieved in a patient with mild to moderate UC, the goal of management is to prevent clinical and endoscopic relapse. The following patients generally require maintenance therapy [
         <a href="#rid40">
          40
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with ulcerative proctitis and &gt;1 disease flare per year
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All patients with ulcerative proctosigmoiditis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All patients with ulcerative colitis proximal to the sigmoid colon (ie, left-sided colitis and extensive colitis)
        </p>
        <p>
        </p>
        <p>
         Patients with ulcerative proctitis and ≤1 flare per year that responds to topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         do not require maintenance therapy, because such patients often have long-term remission without a relapse. If a relapse does occur, symptoms typically resolve quickly with topical mesalamine therapy.
        </p>
        <p class="headingAnchor" id="H1330330613">
         <span class="h3">
          Ulcerative proctitis or proctosigmoiditis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of maintenance therapy depends on the specific agent used to induce remission, the distribution of disease, patient preferences, clinician preferences, and insurance coverage/cost. (See
         <a class="local">
          'Ulcerative proctitis or proctosigmoiditis'
         </a>
         above.)
        </p>
        <p>
         For example  (
         <a class="graphic graphic_table graphicRef86774" href="/z/d/graphic/86774.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with ulcerative proctitis who responded to topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         for induction of remission and who have &gt;1 flare per year, we use a maintenance regimen of one mesalamine suppository (1 gram) every night.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with ulcerative proctosigmoiditis who responded to topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         for induction of remission, we use a maintenance regimen of one mesalamine enema every night.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who are unwilling to use daily topical therapy for long-term maintenance, we reduce the dosing frequency (eg, suppository or enema given every other day or twice weekly), although there are no published data to support this practice [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who required an oral 5-ASA agent to achieve remission, we continue oral 5-ASA therapy to maintain remission. We generally continue the induction dose of oral 5-ASA (ie, &gt;3 grams daily), although some clinicians reduce the dose to 2 to 3 grams per day). Patients with frequent relapses (ie, ≥2 flares per year) may benefit from a higher dose of maintenance oral 5-ASA therapy (ie,
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         &gt;3 grams daily) [
         <a href="#rid45">
          45,46
         </a>
         ]. (See
         <a class="local">
          'Left-sided or extensive colitis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         reduces the risk of relapse for patients with UC in remission [
         <a href="#rid47">
          47,48
         </a>
         ]. In a meta-analysis of seven trials including 555 patients with inactive mild to moderate UC (limited to distal colitis in six trials), patients maintained on topical mesalamine were less likely to relapse compared with patients given placebo (relative risk [RR] 0.60, 95% CI 0.49-0.73) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         Topical glucocorticoids (ie, suppository, foam or enema) are not used for maintenance therapy because of lack of efficacy data and the risk of adverse effects and complications [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1754008218">
         <span class="h3">
          Left-sided or extensive colitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of maintenance therapy depends on the specific agent used to induce remission, the distribution of disease, patient preferences, clinician preferences, and insurance coverage/cost. (See
         <a class="local">
          'Left-sided or extensive colitis'
         </a>
         above.)
        </p>
        <p>
         For example, oral 5-ASA agents and/or topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         formulations are used to maintain remission in patients with left-sided or extensive mild to moderate UC  (
         <a class="graphic graphic_table graphicRef86774" href="/z/d/graphic/86774.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid40">
          40
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral 5-ASA agents
         </strong>
         – For patients who achieved remission with high-dose oral
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         , the dose may be continued at the induction dosing (&gt;3 grams daily) or decreased to 2 to 3 grams daily, and the choice depends on clinician and patient preference. For patients who achieved remission with standard dose oral mesalamine (2 to 3 grams daily), the dose may be continued at the induction dosing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In our experience, a
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         dose of 2 to 3 grams daily is efficacious in maintaining remission for most patients; however, reducing the dose to ≤3 grams per day may increase the risk of relapse for some patients. Patients who flare while on maintenance mesalamine doses ≤3 grams often require a dose increase to prevent recurrence after remission is achieved again [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Oral 5-ASA medications are effective in the maintenance of remission in patients with UC [
         <a href="#rid50">
          50-55
         </a>
         ]. In a meta-analysis of 11 randomized trials, the risk of relapse was lower in patients with inactive UC maintained with oral 5-ASA agents as compared with placebo (RR 0.65, 95% CI 0.55-0.76) [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical
         </strong>
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         – We use topical mesalamine as maintenance therapy regimen primarily for patients with left-sided colitis whose symptoms are well controlled with topical therapy [
         <a href="#rid48">
          48
         </a>
         ]. The dosing frequency is once daily for long-term maintenance therapy. (See
         <a class="local">
          'Ulcerative proctitis or proctosigmoiditis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We typically do not use long-term topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         therapy for patients with extensive colitis.
        </p>
        <p>
        </p>
        <p>
         Both systemic (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ) and locally acting (eg,
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         multimatrix) glucocorticoids are not used for maintenance therapy, because of lack of efficacy data and the risk of adverse effects [
         <a href="#rid37">
          37,56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4248349410">
         <span class="h2">
          Monitoring during remission
         </span>
         <span class="headingEndMark">
          —
         </span>
         We assess patients clinically and with colonoscopy in 6 to 12 months after achieving clinical remission because the therapeutic goal is mucosal healing but correlation between clinical symptoms and endoscopic mucosal appearance is limited. In addition, noninvasive markers of inflammation can be useful. We obtain inflammatory markers including CRP and a fecal biomarker (ie, fecal calprotectin or fecal lactoferrin) at the time of colonoscopy and correlate these tests with the degree of mucosal healing. In some patients with UC, CRP does not correlate with endoscopic findings, and we do not rely solely on CRP for monitoring patients with inactive disease [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         For patients in remission, we continue to measure noninvasive biomarkers every 6 to 12 months. For patients with abnormal results (ie, calprotectin ≥150 mcg/g, positive lactoferrin, or elevated CRP), we typically perform lower endoscopy to assess endoscopic disease activity and guide adjustments in therapy [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         We monitor inflammatory biomarkers because elevated biomarkers have been associated with increased risk of disease relapse. In a meta-analysis of 17 studies with 1286 patients with UC in symptomatic remission, elevated fecal calprotectin (defined in most studies as &gt;150 mcg/g) was associated with higher risk of disease relapse compared with patients who had a normal fecal calprotectin level after a median follow-up of one year (risk ratio [RR] 4.36, 95% CI 3.48-5.47) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1226796987">
         <span class="h1">
          FAILURE TO RESPOND
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients may fail to respond to induction therapy for mild to moderate UC, and such patients are reassessed for disease progression, noncompliance with medical therapy, or an alternative etiology (eg, functional symptoms). (See
         <a class="local">
          'Induction of remission'
         </a>
         above and
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above.):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Compliance – Some patients who are noncompliant with topical therapy report difficulty with administration and retention of enemas due to rectal irritation [
         <a href="#rid57">
          57
         </a>
         ]. Such patients can be treated with a topical glucocorticoid foam preparation rather than a
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         enema. (See
         <a class="local">
          'Ulcerative proctitis or proctosigmoiditis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Refractory disease – Patients who do not have symptomatic improvement with systemic glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         40 mg per day) within one to two weeks of initiating therapy are regarded as having glucocorticoid-refractory disease. Treatment options include a biologic agent (eg, anti-tumor necrosis factor agent) or a small molecule (
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         ). The management of patients with steroid-refractory UC is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">
          "Management of moderate to severe ulcerative colitis in adults", section on 'Intravenous glucocorticoids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1226797055">
         <span class="h1">
          OTHER THERAPIES
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antidiarrheal medications – A short course of symptomatic treatment (7 to 10 days) is an option for patients with mild to moderate UC and no signs of systemic toxicity (eg, fever or tachycardia) who are not responding to therapy with anti-inflammatory medications. For patients who have mild intermittent diarrhea without signs of systemic toxicity, we use
         <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">
          loperamide
         </a>
         as needed in small doses (ie, 2 to 4 mg after an episode of loose stool) for management of diarrhea in this setting because of its efficacy and safety in low doses [
         <a href="#rid58">
          58
         </a>
         ]. An alternative to loperamide is a bile acid sequestrant as needed for mild diarrhea (eg,
         <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">
          cholestyramine
         </a>
         ), and this is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4071.html" rel="external">
          "Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management", section on 'Cholestyramine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medications to avoid – Opioids should be avoided because they can mask the signs and symptoms of an acute abdomen or increase the risk of developing toxic megacolon, and because of their addiction potential. (See
         <a class="medical medical_review" href="/z/d/html/1381.html" rel="external">
          "Toxic megacolon"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although there are limited data, nonsteroidal anti-inflammatory drugs should be avoided due to their potential to exacerbate inflammatory bowel disease [
         <a href="#rid59">
          59,60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H368267851">
         <span class="h1">
          NUTRITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nutrition and dietary therapy for patients with inflammatory bowel disease is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13924.html" rel="external">
          "Nutrition and dietary management for adults with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H110252836">
         <span class="h1">
          HEALTH MAINTENANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is important to perform routine health maintenance, including screening for and prevention of other diseases as well as monitoring for adverse effects of therapy in patients with inflammatory bowel disease (IBD) [
         <a href="#rid61">
          61
         </a>
         ]. The Crohn's and Colitis Foundation provides a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.crohnscolitisfoundation.org%2Fscience-and-professionals%2Feducation-resources%2Fhealth-maintenance-checklists&amp;token=zQklGzRwXLgjJnPpBV2pbBb4xtVTvllLMyFjAa10ksk4vSaWQ5vgqHUFum8fAWVjaRbms7WZWvEEo3RPbXBXFOwCvz6zx1xbZKbavOliGrMNlB31bndfMvgoAi6VhizI&amp;TOPIC_ID=4051" target="_blank">
          health maintenance checklist
         </a>
         for adult patients with IBD [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H110256081">
         <span class="h2">
          Approach to vaccination
         </span>
         <span class="headingEndMark">
          —
         </span>
         As part of our initial evaluation of patients with IBD, we review each patient's vaccination and exposure history [
         <a href="#rid61">
          61
         </a>
         ]. Ideally, this review should be performed before the start of immunosuppressive therapy, when the likelihood of developing a protective immune response to any needed vaccine is highest and when live vaccines can be given safely. In general, patients with IBD require the following inactivated (nonlive) vaccines  (
         <a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid63">
          63
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seasonal nonlive influenza vaccine (annually)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pneumococcal vaccine (for patients who are on or are planning to start immunosuppressive therapy)
        </p>
        <p>
        </p>
        <p>
         In addition, patients are screened for hepatitis B virus before initiating biologic or immunosuppressive therapy, and individuals who are seronegative should be vaccinated for hepatitis B virus [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">
          "Hepatitis B virus immunization in adults"
         </a>
         .)
        </p>
        <p>
         Patients who are not up to date with other routinely recommended vaccines (based on age or other risk factors) should receive any needed inactivated (nonlive) vaccines regardless of immunosuppression. Any needed live vaccines (eg, measles vaccine) should ideally be administered ≥4 weeks prior to the start of immunosuppression. The approach to immunizations for patients with IBD is similar to the care of patients with autoimmune inflammatory rheumatic conditions, and this is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/103773.html" rel="external">
          "Immunizations in autoimmune inflammatory rheumatic disease in adults"
         </a>
         .)
        </p>
        <p>
         Immunization recommendations in the United States result from policies developed by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention [
         <a href="#rid65">
          65
         </a>
         ]. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3884.html" rel="external">
          "Standard immunizations for nonpregnant adults", section on 'Immunization schedule for nonpregnant adults'
         </a>
         .)
        </p>
        <p>
         Patients with IBD are at increased risk for infections due to their underlying disease, malnutrition, surgery, and/or immunosuppressive medications [
         <a href="#rid66">
          66-68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H110256027">
         <span class="h2">
          Cancer screening
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Colorectal cancer
         </strong>
         – Patients with IBD are at increased risk for colorectal cancer (CRC) and should undergo CRC screening with colonoscopy based on the extent and duration of their disease [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4079.html" rel="external">
          "Surveillance and management of dysplasia in patients with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cervical cancer
         </strong>
         – Annual screening for cervical cancer should be performed for women with IBD on immunosuppressive therapy [
         <a href="#rid61">
          61
         </a>
         ]. It is important for clinicians to emphasize the importance of cervical cancer screening for women with IBD on immunosuppressive therapy; compliance with cervical cancer screening tends to be low in women with IBD [
         <a href="#rid70">
          70,71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3220.html" rel="external">
          "Screening for cervical cancer in patients with HIV infection and other immunocompromised states", section on 'Immunosuppressed patients without HIV'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin cancer
         </strong>
         – All IBD patients who have taken, are currently taking, or are planning to start immunomodulators or biologic therapy should undergo annual skin examination by a dermatologist [
         <a href="#rid61">
          61,72
         </a>
         ]. Both melanoma and nonmelanoma skin malignancies are associated with therapies used for IBD. Nonmelanoma skin cancer is associated with past or current use of
         <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">
          6-mercaptopurine
         </a>
         or
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         . Patients should be advised to avoid excessive sun exposure and use a high-strength sunscreen and sun-protective measures [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4064.html" rel="external">
          "Dermatologic and ocular manifestations of inflammatory bowel disease", section on 'Rare dermatologic diseases'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13751.html" rel="external">
          "Selection of sunscreen and sun-protective measures", section on 'Selection of sunscreen products'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H110256103">
         <span class="h2">
          Osteoporosis screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with IBD are at increased risk for bone loss [
         <a href="#rid73">
          73
         </a>
         ]. Screening for osteoporosis with bone mineral density testing should be performed at the time of diagnosis and periodically thereafter in all IBD patients who meet one of the following criteria: postmenopausal, ongoing glucocorticoid treatment, cumulative prior use of glucocorticoids exceeding three months, history of low-trauma fractures, or age over 60 years [
         <a href="#rid61">
          61
         </a>
         ]. The frequency is determined by established guidelines for the general population. (See
         <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">
          "Screening for osteoporosis in postmenopausal women and men"
         </a>
         .)
        </p>
        <p>
         IBD patients on glucocorticoids (any dose with an anticipated duration of ≥3 months) should maintain a total calcium intake of 1200 mg per day and vitamin D intake of 800 international units per day through either diet and/or supplements. Treatment with bisphosphonates for patients with IBD is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2028.html" rel="external">
          "Metabolic bone disease in inflammatory bowel disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H110256110">
         <span class="h2">
          Anxiety/depression screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many IBD patients suffer from anxiety and depression secondary to their disease and should be screened for these conditions [
         <a href="#rid74">
          74-76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/83887.html" rel="external">
          "Screening for depression in adults", section on 'Two-step approach to screening'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H110256095">
         <span class="h2">
          Laboratory monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Periodic laboratory monitoring is necessary to detect complications associated with IBD and side effects of medical therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anemia
         </strong>
         – Approximately 35 to 90 percent of adults with IBD are iron deficient. Other potential causes of anemia in patients with IBD include anemia of chronic disease, vitamin B12 deficiency,
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         deficiency, or drug-induced anemia (eg, patients treated with
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         or thiopurines). (See
         <a class="medical medical_review" href="/z/d/html/5887.html" rel="external">
          "Vitamin and mineral deficiencies in inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with IBD, complete blood count (CBC) should be measured every 6 to 12 months. In patients with anemia or those with low MCV, we also check ferritin, transferrin saturation, and CRP. The CRP is important in the interpretation of the ferritin level, as ferritin is an acute phase reactant. The diagnosis of iron deficiency is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects of therapy
         </strong>
         – For patients on 5-ASA agents, we measure serum creatinine at six weeks, three months, six months, and 12 months after initiation of therapy and then annually [
         <a href="#rid77">
          77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">
          "Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who are initiated on
         <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">
          6-mercaptopurine
         </a>
         or
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , laboratory monitoring (ie, hemoglobin, white blood cell count, platelet count, liver blood tests [serum aminotransferases and total bilirubin]) is performed at short intervals (eg, weekly or every other week) until a maintenance dose is reached. Laboratory testing is continued periodically for the duration of therapy, and the specific monitoring schedules are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">
          "Overview of azathioprine and mercaptopurine use in inflammatory bowel disease", section on 'Dosing and monitoring'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease activity
         </strong>
         – The stool marker, calprotectin, may be used to monitor disease activity in patients with IBD. A systematic review of six studies of 552 IBD (mostly UC) patients in remission showed that ≥2 elevated calprotectin measurements corresponded to a 53 to 83 percent probability of relapse within the next two to three months [
         <a href="#rid78">
          78
         </a>
         ]. (See
         <a class="local">
          'Monitoring during remission'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2097514655">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109937.html" rel="external">
          "Society guideline links: Ulcerative colitis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H88079141">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15613.html" rel="external">
          "Patient education: Ulcerative colitis in adults (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1991.html" rel="external">
          "Patient education: Ulcerative colitis (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/2018.html" rel="external">
          "Patient education: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Defining disease severity and risk
         </strong>
         – Patients with mild to moderate ulcerative colitis (UC) are identified as low risk based on prognostic factors that suggest a nonaggressive form of disease: absence of deep mucosal ulcerations, no extraintestinal manifestations, and diagnosis at age &gt;40 years. These patients usually have mild to moderate symptoms (≤6 stools daily with or without blood) and lack signs of systemic inflammation (ie, normal or minimal elevation in C-reactive protein and/or fecal calprotectin levels). (See
         <a class="local">
          'Disease activity, severity, and risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreatment evaluation
         </strong>
         – For patients with UC who present with symptoms of a disease flare (eg, diarrhea, rectal bleeding), some aspects of the initial evaluation (eg, laboratory and stool studies, lower endoscopy) are repeated to exclude other conditions as a cause for symptoms and to assess the extent and severity of disease. (See
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals of therapy
         </strong>
         – The treatment goal for patients with active UC is to achieve clinical and endoscopic remission by demonstrating complete mucosal healing. Response to therapy can be determined by assessing symptoms and laboratory testing and can be supplemented by endoscopy with biopsies as needed. (See
         <a class="local">
          'Goals of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Induction therapy for ulcerative proctitis or proctosigmoiditis
         </strong>
         – For low-risk patients with ulcerative proctitis or proctosigmoiditis, we suggest topical (rectal)
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         rather than oral mesalamine or observation  (
         <a class="graphic graphic_table graphicRef86774" href="/z/d/graphic/86774.html" rel="external">
          table 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). However, for patients who prefer to avoid the burden of daily topical treatment, it is also reasonable to use oral mesalamine or to observe and initiate treatments if disease progresses. (See
         <a class="local">
          'Initial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with mild to moderate disease confined to the rectum, we typically initiate treatment with
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         suppository once daily  (
         <a class="graphic graphic_algorithm graphicRef138644" href="/z/d/graphic/138644.html" rel="external">
          algorithm 1
         </a>
         ). For patients with mild to moderate disease extending above 18 cm from anal verge into the sigmoid colon, we treat with mesalamine enema once or twice daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For low-risk patients with ulcerative proctitis or proctosigmoiditis who do not have symptom improvement after four weeks of topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         therapy, subsequent options include adding a topical glucocorticoid (eg, suppository, enema), adding an oral 5-aminosalicylic acid (5-ASA) agent, and/or starting an oral glucocorticoid (eg,
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         multimatrix). Selection of second-line therapy depends on patient preferences, product availability, clinician preferences, and prior response to therapy. (See
         <a class="local">
          'Subsequent therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Induction therapy for left-sided or extensive UC
         </strong>
         – For low-risk patients with left-sided or extensive mild to moderate UC, we suggest a combination of an oral 5-ASA agent plus rectal
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         for induction therapy rather than oral 5-ASA monotherapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). We begin high-dose oral mesalamine (ie, &gt;3 grams daily) and mesalamine enemas once daily  (
         <a class="graphic graphic_table graphicRef86774" href="/z/d/graphic/86774.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Left-sided or extensive colitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maintenance therapy
         </strong>
         – We suggest long-term maintenance therapy for the following low-risk patients who have achieved clinical remission with medical therapy (see
         <a class="local">
          'Maintenance of remission'
         </a>
         above) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with ulcerative proctitis and &gt;1 disease flare per year
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with ulcerative proctosigmoiditis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with UC proximal to the sigmoid colon (ie, left-sided colitis and extensive colitis)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The choice of maintenance therapy depends on the specific agent used to induce remission, the distribution of disease, patient preferences, clinician preferences, and insurance coverage/cost. For low-risk patients with mild to moderate UC in remission, the goal of management is to prevent clinical and endoscopic relapse.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Health maintenance
         </strong>
         – Routine health maintenance, including screening for and prevention of other diseases as well as monitoring for adverse effects of therapy, is an important aspect of the care of patients with inflammatory bowel disease. (See
         <a class="local">
          'Health maintenance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2638367146">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff thank Dr. Richard MacDermott for his contributions as author to prior versions of this topic review.
        </p>
        <p>
         The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ko CW, Singh S, Feuerstein JD, et al. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019; 156:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol 2019; 114:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh S, Ananthakrishnan AN, Nguyen NH, et al. AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis. Gastroenterology 2023; 164:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           TRUELOVE SC, WITTS LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317:1625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 Suppl A:5A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996; 31:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009; 104:2080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dassopoulos T, Cohen RD, Scherl EJ, et al. Ulcerative Colitis Care Pathway. Gastroenterology 2015; 149:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis 2015; 9:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007; 52:2063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prantera C, Davoli M, Lorenzetti R, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988; 10:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002; 14:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makkar R, Bo S. Colonoscopic perforation in inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2013; 9:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther 1999; 13:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malchow H, Gertz B, CLAFOAM Study group. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Aliment Pharmacol Ther 2002; 16:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman NJ, Brown ML, Phillips SF, et al. Distribution of mesalamine enemas in patients with active distal ulcerative colitis. Mayo Clin Proc 1992; 67:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farthing MJ, Rutland MD, Clark ML. Retrograde spread of hydrocortisone containing foam given intrarectally in ulcerative colitis. Br Med J 1979; 2:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamet M, Ptak T, Dallaire C, et al. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm Bowel Dis 2005; 11:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andus T, Kocjan A, Müser M, et al. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis 2010; 16:1947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019; 156:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010; :CD004115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kam L, Cohen H, Dooley C, et al. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 1996; 91:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92:1867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998; 41:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandborn WJ, Bosworth B, Zakko S, et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology 2015; 148:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol 2007; 21:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137:1934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           d'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997; 92:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011; 33:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54:960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frühmorgen P, Demling L. On the efficacy of ready-made-up commercially available salicylazosulphapyridine enemas in the treatment of proctitis, proctosigmoiditis and ulcerative colitis involving rectum, sigmoid and descending colon. Hepatogastroenterology 1980; 27:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vecchi M, Meucci G, Gionchetti P, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001; 15:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143:1218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Haens GR, Kovács A, Vergauwe P, et al. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis 2010; 4:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carter MJ, Lobo AJ, Travis SP, IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 Suppl 5:V1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; :CD006792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 2015; 148:1035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kane S. Medication adherence and the physician-patient relationship. Am J Gastroenterol 2002; 97:1853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10:CD000544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckland A, Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Aliment Pharmacol Ther 2008; 28:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 11:CD004118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford AC, Khan KJ, Sandborn WJ, et al. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012; 107:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon G, Pruitt RE, Ringold M, et al. Once daily 1.5 g granulated mesalamine is effective and safe in maintenance of remission in mild to moderate UC (abstract). Am J Gastroenterol 2008; 103:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lichtenstein GR, Merchant K, Shaw A, et al. Once daily 1.5 granulated mesalamine effectively maintains remission in patients with ulcerative colitis who switch from different 5-ASA formulations (abstract). Am J Gastroenterol 2008; 103(s1):s429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7:762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010; 138:1286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan N, Abbas AM, Bazzano LA, et al. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther 2012; 36:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrett KE, Dharmsathaphorn K. Pharmacological aspects of therapy in inflammatory bowel diseases: antidiarrheal agents. J Clin Gastroenterol 1988; 10:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long MD, Kappelman MD, Martin CF, et al. Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease. J Clin Gastroenterol 2016; 50:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kvasnovsky CL, Aujla U, Bjarnason I. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol 2015; 50:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2017; 112:241.
          </a>
         </li>
         <li class="breakAll">
          https://www.crohnscolitisfoundation.org/science-and-professionals/programs-materials/health-maintenance-checklist.pdf (Accessed on May 21, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim DK, Hunter P, Advisory Committee on Immunization Practices. Recommended Adult Immunization Schedule, United States, 2019. Ann Intern Med 2019; 170:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahier JF, Yazdanpanah Y, Colombel JF, Travis S. The European (ECCO) Consensus on infection in IBD: what does it change for the clinician? Gut 2009; 58:1313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murthy SK, Feuerstein JD, Nguyen GC, Velayos FS. AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. Gastroenterology 2021; 161:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moscicki AB, Flowers L, Huchko MJ, et al. Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection. J Low Genit Tract Dis 2019; 23:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long MD, Porter CQ, Sandler RS, Kappelman MD. Suboptimal rates of cervical testing among women with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009; 7:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clowry J, Sheridan J, Healy R, et al. Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study. J Eur Acad Dermatol Venereol 2017; 31:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2018; 113:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hashash JG, Vachon A, Ramos Rivers C, et al. Predictors of Suicidal Ideation Among IBD Outpatients. J Clin Gastroenterol 2019; 53:e41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hashash JG, Chedid V, Vachon A, et al. Predictors of Depression in Outpatients With IBD. Gastroenterology 2015; 148:S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunliffe RN, Scott BB. Review article: monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heida A, Park KT, van Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis 2017; 23:894.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4051 Version 46.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30576644" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30840605" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : ACG Clinical Guideline: Ulcerative Colitis in Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36822736" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13260656" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cortisone in ulcerative colitis; final report on a therapeutic trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3317057" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16151544" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8833356" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Changes in extent of ulcerative colitis: a study on the course and prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19436273" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The natural history of pediatric ulcerative colitis: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26025078" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Ulcerative Colitis Care Pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25518058" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17436102" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3356884" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15472532" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : C-reactive protein as a marker for inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17924558" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11943955" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24729766" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Colonoscopic perforation in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10102972" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11876694" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1545592" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Distribution of mesalamine enemas in patients with active distal ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/509112" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Retrograde spread of hydrocortisone containing foam given intrarectally in ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15973115" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20310020" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30576642" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20091560" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8677990" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9382054" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9510317" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25644096" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16384751" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Adverse effects of topical glucocorticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18080055" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19766640" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9219787" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21255059" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15951542" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6110627" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : On the efficacy of ready-made-up commercially available salicylazosulphapyridine enemas in the treatment of proctitis, proctosigmoiditis and ulcerative colitis involving rectum, sigmoid and descending colon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11148445" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22892337" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Once-daily budesonide MMX®extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23436336" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21122499" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX®9 mg extended-release tablets in patients with active left-sided ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15306569" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Guidelines for the management of inflammatory bowel disease in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18425970" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Traditional corticosteroids for induction of remission in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25747596" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21407179" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12135059" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Medication adherence and the physician-patient relationship.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23076890" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18808444" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23152224" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22083024" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22890223" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Once daily 1.5 g granulated mesalamine is effective and safe in maintenance of remission in mild to moderate UC (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Once daily 1.5 granulated mesalamine effectively maintains remission in patients with ulcerative colitis who switch from different 5-ASA formulations (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19375519" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18272546" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20064514" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21407188" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11487534" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22882428" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3282003" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Pharmacological aspects of therapy in inflammatory bowel diseases: antidiarrheal agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26485106" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25314574" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28071656" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28071656" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24421306" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21172250" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30716757" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Recommended Adult Immunization Schedule, United States, 2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19749130" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The European (ECCO) Consensus on infection in IBD: what does it change for the clinician?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23295276" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Increased risk of pneumonia among patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23240738" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34416977" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30907775" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18996498" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Suboptimal rates of cervical testing among women with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28045204" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12612917" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : AGA technical review on osteoporosis in gastrointestinal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29610508" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : ACG Clinical Guideline: Management of Crohn's Disease in Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30036241" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Predictors of Suicidal Ideation Among IBD Outpatients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Predictors of Depression in Outpatients With IBD
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11929382" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Review article: monitoring for drug side-effects in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28511198" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
